Business Wire

Veteran US E-Commerce Entrepreneur Frank Poore to join Board of ENGAGE XR

Share

US e-commerce entrepreneur, and founder and CEO of CommerceHub, Frank Poore has been appointed as a Non-executive Director of leading virtual reality ('VR') technology company, ENGAGE XR Holdings plc (“ENGAGE XR”).

Frank brings a wealth of entrepreneurial and business experience to ENGAGE XR with over 25 years as an e-commerce innovator and visionary. As founder and CEO of CommerceHub, Frank built an industry-leading company that enables $30 billion in recurring e-commerce sales for 15,000 of the world’s largest retailers, brands, distributors, and marketplaces.

Based in Europe, ENGAGE XR (which is changing its name from VR Education Holdings plc) is listed on the London Stock Exchange. ENGAGE XR is focused on becoming a leading global provider of virtual communications solutions through its proprietary software platform, ENGAGE. ENGAGE provides users with a platform for creating, sharing, and delivering VR content for communication, training, and online events. The Company has announced the development of a new fully featured corporate metaverse, codenamed "ENGAGE Oasis", with the launch expected in the first half of 2022.

In the first six months of 2021, the Company’s revenue increased by 83% to €1.25 million as demand for VR as a communications tool, was accelerated by the pandemic. Since ENGAGE’s launch in 2019, the number of commercial customers has increased to over 130, as well as the Company making significant progress in the roll-out of ENGAGE in China through its partnership with HTC and entering the Middle East for the first time. ENGAGE customers include Abbott Laboratories, BMW Motorsport, Facebook, HTC, MongoDB, and the US State Department.

As well as serving on the Board, Frank will work with the management of ENGAGE XR to help expand the Company’s sales function to help achieve its goal of becoming a leading global provider of virtual communications and support the successful roll-out of ENGAGE Oasis.

As CEO, Frank led CommerceHub through enormous periods of growth, resulting in major milestone events including international expansion, two significant acquisitions, and a successful public floatation on Nasdaq. CommerceHub’s platform and business model were also highly respected for generating industry-leading EBITDA returns. Frank created four successful liquidity events for CommerceHub shareholders - first through a sale of CommerceHub to QVC/Comcast Corporation in 2006, second via public offering in 2016 on Nasdaq, third through a $1 billion take-private sale of CommerceHub to GTCR and Sycamore Partners in 2018, and most recently through a majority sale to Insight Partners and Goldman Sachs for nearly $2 billion in December 2020.

David Whelan, CEO of ENGAGE XR, commented: “With over 25 years’ experience as a successful entrepreneur, building a company with a strong sales and technology focus, and a track record of delivering value for global multinational businesses, Frank is a major addition to our Board. His experience will be invaluable as we expand our ENGAGE metaverse offering particularly in North America working together to achieve our ambitious medium and long-term growth targets.”

Frank Poore said: “I am excited to join the Board of VRE and to work with VR pioneers like David and Sandra. As companies embrace remote work, they will need new ways to manage their culture and team chemistry. ENGAGE is already well-positioned as the “office of the future” by enabling distributed teams to come together into a virtual office, conference room, auditorium, classroom, or coffee shop to create a sense of presence and to foster collaboration, creativity, and serendipity. The development of ENGAGE Oasis is especially exciting and it can establish itself as the go-to virtual world where global organizations come to interact with each other, and their stakeholders. I believe that my background and personality will bring a disruptive yet collaborative spirit that can help unlock substantial value for shareholders.”

Website: https://www.engagexrholdings.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SEC Newgate
Robin Tozer / Isabelle Smurfit
VReducation@secnewgate.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye